@article{612ffee623d2465a905cebc597fa456b,
title = "Mild cognitive impairment",
abstract = "Mild cognitive impairment is a syndrome defined as cognitive decline greater than expected for an individual's age and education level but that does not interfere notably with activities of daily life. Prevalence in population-based epidemiological studies ranges from 3% to 19% in adults older than 65 years. Some people with mild cognitive impairment seem to remain stable or return to normal over time, but more than half progress to dementia within 5 years. Mild cognitive impairment can thus be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension. The amnestic subtype of mild cognitive impairment has a high risk of progression to Alzheimer's disease, and it could constitute a prodromal stage of this disorder. Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia.",
author = "Serge Gauthier and Barry Reisberg and Michael Zaudig and Petersen, {Ronald C.} and Karen Ritchie and Karl Broich and Sylvie Belleville and Henry Brodaty and David Bennett and Howard Chertkow and Cummings, {Jeffrey L.} and {de Leon}, Mony and Howard Feldman and Mary Ganguli and Harald Hampel and Philip Scheltens and Tierney, {Mary C.} and Peter Whitehouse and Bengt Winblad",
note = "Funding Information: None of the participants listed works for a pharmacological company as an employee. No drug has been approved for the indication of mild cognitive impairment. H Brodaty is a consultant or speaker for, or has received investigator support from, Eisai, Janssen, Lundbeck, Novartis, Pfizer, Sanofi, and Servier. M de Leon is a consultant to GE Health Care and has received educational grants from Janssen and Forest. H Feldman has received grants from Eisai, Glaxo, Jenssen, Lilly, and Pfizer, and has acted as a consultant or speaker for AstraZeneca, Axonynx, Eisai, Forest, GlaxoSmithKline, Janssen, Lundbeck, Myriad, Novartis, Pfizer, Targacept, Sanofi, and Servier. S Gauthier is a consultant or speaker for GlaxoSmithKline, Hoffman-LaRoche, Janssen, Lundbeck, Merz, Neurochem, Novartis, Pfizer, Sanofi, and Servier. B Reisberg has received grants from Forest, Novartis, and Janssen, and has been a consultant or speaker for Ajinomoto, Amersham, Aventis, Bristol Meyers, Squibb, Glaxo, Janssen, Lundbeck, and Merz. R C Petersen has acted as a consultant for Elan Pharmaceuticals and GE Global Research. P Scheltens has been a consultant or speaker for Eisai, Janssen, Merck, Novartis, and Servier. M C Tierney has received a research grant from Shire Biochem. P J Whitehouse has been a consultant or speaker for AstraZeneca, Bristol Myers Squibb, Cerebrio/Avenir, Forest, Janssen, Sanofi, Takeda, and Pfizer. B Winblad has been a consultant for advisory boards with Janssen, Merz, Lundbeck, Novartis, Pfizer, Sanofi, and Servier. M Zaudig has acted as a consultant to Pfizer. ",
year = "2006",
month = apr,
day = "15",
doi = "10.1016/S0140-6736(06)68542-5",
language = "English (US)",
volume = "367",
pages = "1262--1270",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9518",
}